Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-01056-6
Abstract: Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant… read more here.
Keywords: post allotransplant; cd19 positive; donor derived; cell ... See more keywords